Prostate-specific antigen (PSA) testing for early detection of prostate cancer in asymptomatic men is controversial, remaining a significant challenge for the NHS because of uncertainty that any mortality reduction from PSA-based screening outweighs the impact of overdiagnosis and overtreatment on men’s quality of life and healthcare systems. Here, KLK3 is linked to prostate cancer.